Shots:

• The company will present data from the final analysis of P-IIIb STASEY study of Hemlibra (emicizumab) reinforcing the safety & efficacy of Hemlibra in people with hemophilia A with factor VIII inhibitors
• Spark will share data from the P-I/II study of SPK-8011- demonstrating that hepatocyte expression of factor VIII can be stable and durable up to 4yrs. following vector administration- with an acceptable safety profile. The results showed 93% reduction in ABR and a 97% reduction in annualized infusion rate
• Additionally- the company will present the data from the 2017 CHESS PAEDs study that demonstrated the treatment needs & clinical burden in children with hemophilia A

  Ref: Roche | Image: Roche